Abstract In the United States, prostate cancer is the most commonly diagnosed non–skin
cancer and the second leading cause of cancer death. The American Cancer Society …

Prostate cancer incidence and mortality rates vary worldwide. In the United States, prostate
cancer is the most common malignancy affecting men and is the second-leading cause of …

Background Prostate cancer is a significant public health issue in the United States. It is the
most commonly diagnosed non-skin cancer and the second leading cause of cancer death …

The increased use of prostate-specific antigen (PSA) in screening for preclinical disease
after 1985 is thought to be a major determinant of the changing patterns in prostate cancer …

Background Although there is uncertainty about the effect of prostate-specific antigen (PSA)
screening on the rate of prostate cancer death, there is little uncertainty about its effect on …

National-level data that characterize contemporary prostate cancer patients are limited. We
used 2004–2005 data from the Surveillance, Epidemiology, and End Results Program to …

BACKGROUND Temporal trends in prostate cancer incidence and death rates have been
attributed to changing patterns of screening and improved treatment (mortality only), among …

Purpose To our knowledge it is unknown whether decreases in the prevalence of prostate
specific antigen screening and prostate cancer incidence rates following the USPSTF …

Interpretation of cancer incidence and mortality rates in a defined population requires an
understanding of multiple complex and interacting factors. These factors include the …

PURPOSE: We assess the influence of prostate specific antigen screening on trends in
mortality rates in patients with prostate cancer. MATERIALS AND METHODS: The incidence …